While the classification of BRCA2 c.5159C>A (S1720∗) as a pathogenic variant is highly unlikely to change, the finding of VUSs in four Kenyan patients may require recontact of these patients in future in the event of reinterpretation, following family screening, functional studies or extended testing of additional unrelated breast cancer patients (Richards et al., 2015). This evidence concerns the gene BRCA2 and breast cancer.